The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/5000 - 1/15000. Detects a band of approximately 39 kDa (predicted molecular weight: 39 kDa).
Use at 1-4 µg/mg of lysate.
Use at an assay dependent concentration. PubMed: 21844210
1/500 - 1/2000.
May be directly involved in regulating the cleavage of polar spindle microtubules and is a key regulator for the onset of cytokinesis during mitosis. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Phosphorylates 'Ser-10' and 'Ser-28' of histone H3 during mitosis. Required for kinetochore localization of BUB1 and SGOL1. Interacts with INCENP.
High level expression seen in the thymus. It is also expressed in the spleen, lung, testis, colon, placenta and fetal liver. Expressed during S and G2/M phase and expression is up-regulated in cancer cells during M phase.
Note=Disruptive regulation of expression is a possibile mechanism of the perturbation of chromosomal integrity in cancer cells through its dominant-negative effect on cytokinesis.
Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. Aurora subfamily. Contains 1 protein kinase domain.
Ubiquitinated by different BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complexes. Ubiquitinated by the BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex, ubiquitination leads to removal from mitotic chromosomes and is required for cytokinesis. During anaphase, the BCR(KLHL21) E3 ubiquitin ligase complex recruits the CPC complex from chromosomes to the spindle midzone and mediates the ubiquitination of AURKB. Ubiquitination of AURKB by BCR(KLHL21) E3 ubiquitin ligase complex may not lead to its degradation by the proteasome.
Nucleus. Chromosome. Chromosome > centromere. Cytoplasm > cytoskeleton > spindle. Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalized with gamma tubulin in the mid-body.
Aurora and Ipl1 like midbody associated protein 1 antibody
Aurora kinase B antibody
Aurora related kinase 2 antibody
Aurora- and Ipl1-like midbody-associated protein 1 antibody
Aurora-related kinase 2 antibody
Aurora/IPL1 related kinase 2 antibody
Aurora/IPL1-related kinase 2 antibody
Protein phosphatase 1 regulatory subunit 48 antibody
Serine/theronine kinase 12 antibody
Serine/threonine protein kinase 12 antibody
Serine/threonine-protein kinase 12 antibody
Serine/threonine-protein kinase aurora-B antibody
Immunocytochemistry/ Immunofluorescence - Anti-Aurora B antibody (ab70238)
Immunocytochemistry/Immunofluorescence analysis of asynchronous HeLa cells labelling Aurora B with ab70238 at 0.5µg/ml in A and at 2µg/ml in B. A FITC-conjugated anti-rabbit IgG was used as the secondary antibody in A. A Texas Red-conugated anti-rabbit IgG was used as the secondary antibody in B.
Western blot - Aurora B antibody (ab70238)
All lanes : Anti-Aurora B antibody (ab70238) at 1/10000 dilution
Lane 1 : Whole cell lysate from non-adherent HeLa cells treated with nocodazole (20h)
Lane 2 : Whole cell lysate from adherent HeLa cells treated with nocodazole (20h)
Lane 3 : Whole cell lysate from non-adherent HeLa cells treated with nocodazole (20h)
Lane 4 : Whole cell lysate from adherent HeLa cells treated with nocodazole (20h)
Lysates/proteins at 50 µg per lane.
Developed using the ECL technique
Predicted band size : 39 kDa Observed band size : 39 kDa Additional bands at : 28 kDa,36 kDa. We are unsure as to the identity of these extra bands.Detection time: 10 secs (lanes 1,2) or 30 secs (lanes 3,4)
Western blot - Aurora B antibody (ab70238)
All lanes : Anti-Aurora B antibody (ab70238) at 0.1 µg/ml
Lane 1 : HeLa whole cell lysate from an asynchronous culture Lane 2 : HeLa whole cell lysate treated with cycloheximide for 12 hours Lane 3 : HeLa whole cell lysatetreated with cycloheximide for 24 hours Lane 4 : HeLa whole cell lysate
treated with cycloheximide for 36 hours Lane 5 : HeLa whole cell lysate treated with nocodazole for 20 hours